Pyridoxine

Summary

Pyridoxine (CHEMBL1364) is an approved small-molecule cofactor (ATC A11HA02); indicated across 30 conditions including chronic kidney disease and osteoporosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A11HA02
• Indications: 30 conditions
• Clinical trials: 84
• Chemistry: 169.18 Da · C8H11NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1364
Name	Pyridoxine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	1054
ChEBI	CHEBI:16709
ATC	A11HA02
Molecular formula	C8H11NO3
Molecular weight	169.18
InChIKey	LXNHXLLTXMVWPM-UHFFFAOYSA-N

SMILES: CC1=NC=C(C(=C1O)CO)CO

IUPAC name: 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol

ChEBI definition: A hydroxymethylpyridine with hydroxymethyl groups at positions 4 and 5, a hydroxy group at position 3 and a methyl group at position 2. The 4-methanol form of vitamin B6, it is converted intoto pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters, sphingolipids and aminolevulinic acid.

Pharmacological roles (ChEBI): cofactor.

Other ChEBI roles (chemical / environmental): human metabolite, Saccharomyces cerevisiae metabolite, Escherichia coli metabolite, mouse metabolite.

Also known as: Adermine, Hexabione, M.v.i.-12, NSC-759148, Piridoxina, Pyridoxine, Pyridoxine (vit b6), Pyridoxine component of vitaped, Pyridoxol, Vitamin b-6, Vitamin b6, Vitamin v6

Parent form; salt/anhydrous children: CHEMBL1200756

Patent coverage: 46,020 distinct patent families (107,988 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 107,987 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Lysine-specific demethylase 4E, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Aldehyde dehydrogenase 1A1, 3-hydroxyacyl-CoA dehydrogenase type-2.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

30 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	4	MONDO:0005300	EFO:0003884
osteoporosis	4	MONDO:0005298	EFO:0003882
anemia	4	MONDO:0002280	MONDO:0002280
type 2 diabetes mellitus	4	MONDO:0005148	MONDO:0005148
movement disorder	3	MONDO:0005395	EFO:0004280
hand-foot syndrome	3	MONDO:0700048	EFO:1001893
metabolic dysfunction-associated steatotic liver disease	3	MONDO:0013209	EFO:0003095
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
tuberculosis	3	MONDO:0018076	MONDO:0018076
epilepsy	2	MONDO:0005027	EFO:0000474
lymphoma	2	MONDO:0005062	EFO:0000574
HIV infectious disease	2	MONDO:0005109	EFO:0000764
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
heart failure	2	MONDO:0005252	EFO:0003144
atherosclerosis	2	MONDO:0005311	EFO:0003914
psychotic disorder	2	MONDO:0005485	EFO:0005407
myocardial infarction	2	MONDO:0005068	EFO:0000612
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
pulmonary tuberculosis	2	MONDO:0006052	EFO:1000049
myocardial ischemia	2	MONDO:0024644	EFO:1001375
heart disorder	2	MONDO:0005267	EFO:0003777
alcoholic hepatitis	2	MONDO:0001505	EFO:1001345
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
alcoholic fatty liver disease	2	MONDO:0021104	MONDO:0021104
pulmonary alveolar proteinosis	1	MONDO:0001437	MONDO:0001437
neoplasm	1	MONDO:0005070	MONDO:0004992

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 84.

Phase distribution

Phase	Trials
Not specified	28
PHASE2	18
PHASE3	15
PHASE2/PHASE3	8
PHASE4	7
PHASE1	5
PHASE1/PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05411744	PHASE4	ACTIVE_NOT_RECRUITING	One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
NCT07029698	PHASE4	RECRUITING	A Study to See if a Combination of Vitamins That is Injected Into a Muscle is as Good and Safe as a Vitamin That is Taken by Mouth
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00763633	PHASE4	UNKNOWN	B6 Treatment for Nausea and Vomiting in Pregnancy
NCT02051842	PHASE4	UNKNOWN	Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis
NCT05008354	PHASE4	COMPLETED	Effect of Pyridoxine on Behavioral Adverse Events of Levetiracetam
NCT06020300	PHASE4	UNKNOWN	Short Course Low Dose Oral Colchicine After ST Elevation Myocardial Infarction(STEMI)
NCT05994742	PHASE3	ACTIVE_NOT_RECRUITING	An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM
NCT06618573	PHASE2/PHASE3	RECRUITING	Safety of Administering Isoniazid to SLE Patients to Prevent TB
NCT00001033	PHASE3	COMPLETED	The Treatment of Tuberculosis in HIV-Infected Patients
NCT00004734	PHASE3	COMPLETED	Vitamin Therapy for Prevention of Stroke
NCT00056225	PHASE3	COMPLETED	VITAL - VITamins to Slow ALzheimer’s Disease (Homocysteine Study)
NCT00114400	PHASE2/PHASE3	COMPLETED	BVAIT: B-Vitamin Atherosclerosis Intervention Trial
NCT00200226	PHASE3	COMPLETED	Oral Misoprostol Before Endometrial Biopsy
NCT00245050	PHASE3	COMPLETED	Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
NCT00296036	PHASE3	COMPLETED	Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
NCT00446147	PHASE3	COMPLETED	Study of Pyridoxine for Hand-Foot Syndrome
NCT00486213	PHASE3	TERMINATED	Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
NCT00559858	PHASE3	UNKNOWN	Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer
NCT00659269	PHASE3	COMPLETED	A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
NCT00704990	PHASE2/PHASE3	COMPLETED	Combination Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT01128244	PHASE2/PHASE3	COMPLETED	Vitamin B6 Effects for Women Taking Birth Control Pills
NCT01426490	PHASE2/PHASE3	UNKNOWN	The Effects of Vitamin B-6 Status on Homocysteine, Oxidative Stress, One-carbon Metabolism and Methylation: Cross-section, Case-control, Intervention and Follow-up Studies in Colorectal Cancer
NCT01440621	PHASE3	COMPLETED	Modafinil in Cancer Related Fatigue
NCT01908452	PHASE3	WITHDRAWN	Pyridoxal Kinase Activity in Tardive Dyskinesia
NCT01964001	PHASE2/PHASE3	COMPLETED	The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer
NCT02541045	PHASE3	WITHDRAWN	Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
NCT02563327	PHASE3	COMPLETED	Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
NCT03790345	PHASE2/PHASE3	UNKNOWN	Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
NCT06390787	PHASE2/PHASE3	COMPLETED	The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics
NCT00000541	PHASE2	COMPLETED	Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
NCT00004758	PHASE2	COMPLETED	Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment
NCT00070434	PHASE2	WITHDRAWN	S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
NCT01243242	PHASE2	COMPLETED	Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
NCT01391962	PHASE2	COMPLETED	Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
NCT01504295	PHASE2	COMPLETED	A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease
NCT01601626	PHASE2	TERMINATED	Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
NCT01685281	PHASE2	COMPLETED	Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
NCT01730313	PHASE2	WITHDRAWN	Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012
NCT01785186	PHASE2	COMPLETED	Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).